EchoGo for chemotherapy patients
EchoGo Platform for automated processing of transthoracic echocardiograms for assessment of cardiac parameters in patients undergoing chemotherapy with cardiotoxic drugs.
New chemotherapeutic agents have improved the treatment of several types of cancer - in particular breast cancer. However, this comes at increased risk of cardiac adverse events. Measurement of the LV ejection fraction (EF) and global longitudinal strain (GLS) have been used to assess the risk of cancer treatment related cardiac dysfunction (CRTCD) prior to chemotherapy with cardiotoxic drugs such as Adriamycin and Trastuzumab. EF and GLS are also used to monitor LV function during chemotherapy. In particular, GLS has been advocated to allow detection of subclinical cardiac dysfunction.
It is clear that current measures of EF and GLS in chemotherapeutic patients continues to be unreliable, variable and manual in nature. Thus, new tools to evaluate cardiac function and improve clinical workflows in this patient group remains a priority for the improvement of patient care.
It is proposed within this project that the advance technology platform and image analysis expertise of Ultromics will be combined with the clinical input of partnered clinical sites to address the current unmet needs facing chemotherapeutic patients.
To utilize the EchoGo Platform for automated processing of transthoracic echocardiograms for assessment of cardiac parameters in patients undergoing chemotherapy.
EchoGo is an automated platform which enables clinicians to interpret echocardiograms efficiently and accurately.
It aims to:
- Improves patient outcomes by assists clinicians in making decisions that can improve care delivery and outcomes
- Automate complex measurements, standardizing the quality of image interpretation
- Reduces variability by allowing clinicians with a wide range of experience to consistently interpret cardiac parameteres and improve reproducibility.
1. Compare the performance of automated contouring for EF and GLS measurements in resting transthoracic echocardiograms with
- Conventional measurement acquisitions
- With and without the application of contrast agents
2. Demonstrate connectivity and develop optimal clinical workflow with clinicians to assess whenreports should be returned e.g. visit-by-visit.
3. Asses the feasibility of an automated quality review process of the acquired echocardiogramimages in a clinic.
4. Evaluate the potential clinical and economic benefit of automated EF and GLS measurements.